UT MD Anderson and P-Cure collaborate to advance first compact upright dual-modality proton and helium ion therapy platform
The University of Texas MD Anderson Cancer Center and P-Cure Ltd. today announced a strategic alliance to advance the development and clinical validation of a next-generation particle therapy platform designed to deliver both proton and helium ion therapy from a single compact upright treatment system.
The collaboration combines UT MD Anderson's expertise in radiation oncology, particle therapy and translational cancer research...
UT MD Anderson announces historic expansion of cancer care facilities
The University of Texas MD Anderson Cancer Center today announced the historic expansion of its Texas Medical Center (TMC) campus through...
Susan Bullman receives TAMEST Mary Beth Maddox Award for breakthrough tumor microbiome research
Susan Bullman, Ph.D., associate professor of Immunology and Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer...
Allison Institute convenes leading scientists and clinicians for fourth annual scientific symposium on frontiers of immunotherapy
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center hosted its fourth annual scientific symposium, “Immune Set Points: Stress, Wellness and System Control,...